Published in Cancer Weekly, June 12th, 2006
Treatment with PV-10 was well tolerated by all subjects, with no evidence of systemic or serious local side effects. Most subjects have exhibited evidence of efficacy, ranging from tumor shrinkage to complete ablation. Several also exhibited subsequent shrinkage of untreated tumors, a response characteristic of the "bystander effect." These results achieve the primary study endpoints of safety and preliminary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.